Genetics Generation Advancement Corp. (TPEX:4160)
40.05
+0.05 (0.13%)
Jun 3, 2026, 1:30 PM CST
TPEX:4160 Revenue
Genetics Generation Advancement had revenue of 149.38M TWD in the quarter ending March 31, 2026, with 4.19% growth. This brings the company's revenue in the last twelve months to 609.13M, down -4.58% year-over-year. In the year 2025, Genetics Generation Advancement had annual revenue of 603.11M, down -8.88%.
Revenue (ttm)
609.13M
Revenue Growth
-4.58%
P/S Ratio
1.77
Revenue / Employee
5.86M
Employees
104
Market Cap
1.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 603.11M | -58.74M | -8.88% |
| Dec 31, 2024 | 661.86M | 69.36M | 11.71% |
| Dec 31, 2023 | 592.50M | 44.69M | 8.16% |
| Dec 31, 2022 | 547.81M | 28.30M | 5.45% |
| Dec 31, 2021 | 519.51M | 76.38M | 17.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BIONET | 1.26B |
| DIVA Laboratories | 884.63M |
| Kim Forest Enterprise | 549.14M |
| Sofiva Genomics | 382.82M |
| Welgene Biotech | 381.82M |
| Pharmigene | 199.89M |
| Puriblood Medical | 82.34M |